Skip to content

Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts

Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts Versus Acellular Bone Graft Substitutes for Augmentation in the Treatment of Proximal Humeral Fractures as Model for Fractures of Osteoporotic Bone - a Prospective Randomized First in Men Proof of Principle Trial

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01532076
Acronym
ROBUST
Enrollment
8
Registered
2012-02-13
Start date
2012-06-30
Completion date
2014-09-30
Last updated
2014-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporotic Fractures

Keywords

osteoporosis, prox. humeral fracture, geriatric trauma, mesenchymal stem cells

Brief summary

Failure rates of up to 30% are reported after proximal humeral fractures despite angular-stable devices. This may devastate not only the functional outcome but also the independence of elderly patients. To increase bone mineral density and thereby holding-strength augmentation is an option. Autologous bone-graft, as current gold-standard, though is questionable in osteoporosis since osteoprogenitors are dysfunctional and the harvesting-morbidity considerable. Adipose tissue seems an alternative cell-source even in presence of osteoporosis. Stromal vascular fraction (SVF) cells isolated from lipoaspirates display osteogenic and vasculogenic potential and can be harvested in high numbers. Expansion associated with costly good-manufacturers-practice facilities is avoidable, so are repeated interventions. These cells have been successfully used to generate osteogenic composite grafts with intrinsic vascularity in preclinical models. For translation into clinical practice after a 20 patient external pilot a prospective randomized controlled trial with 270 patients is planned. For the trial lipoaspiration precedes open reduction and internal fixation in individuals over 60 years presenting with a proximal humeral fracture after low-energy trauma. Cells are isolated (Cellution®800/CRS) and wrapped around hydroxyapatite microgranules after embedding in a fibrin-gel for augmentation of the typical bone-void. Clinical/radiological follow-up is at 6 and 12 weeks for immediate complications and after 6, 9 and 12 months. Functional assessment is performed after 6 weeks, 6 and 12 months using the Quick-Dash- and Constant-Score. The primary outcome is a reduction in secondary dislocation by 50% during the first postoperative year. Secondary dislocation is diagnosed on plain radiographs by an independent board certified radiologist specialised in musculoskeletal imaging if one or more of the following criteria are met: * More than 20° varus collapse of the humeral head fragment in relation to the humeral shaft * Screw penetration through the humeral head

Interventions

PROCEDURECellularized composite graft augmentation

liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules

PROCEDUREAcellular composite graft augmentation

Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Presentation with an isolated proximal humeral fracture after a low-energy trauma (e.g. falling from a standing position) and: * indication for open reduction and internal fixation with a proximal humeral locking plate (PHILOS®, Synthes, Switzerland) after low energy trauma * displacement of more than 1 cm between fragments and/or * angulation of 45° or more between the fragments and/or * dislocation of the greater tuberosity of 5 mm or more and/or * patient specific factors like high functional demand etc * age \> 50 years * postmenopausal status (i.e. 12 continuous month without menstruation) * informed consent in surgery and study participation

Exclusion criteria

* Psychiatric disorder severely impairing co-operation (dementia mini mental Status (MMS) \<24, schizophrenia, major depression) * Pathological fractures caused by other conditions * Fracture-related nerve injury * Malignancies under current treatment (i.e. chemotherapy, radiotherapy etc.) * BMI \<20 kg/m2 * Known hypersensitivity to one of the graft components * Participation in a clinical trial within 3 month before enrolment

Design outcomes

Primary

MeasureTime frameDescription
Development of secondary dislocation within 12 months postoperative12 months postoperativeSecondary dislocation within the first year postoperative on plain radiographs in ap. and Neer projections diagnosed by an independent radiologist specialized in musculoskeletal imaging in case of * more than 20° varus collapse of the humeral head fragment in relation to the humeral shaft * screw penetration through the humeral head

Secondary

MeasureTime frameDescription
Functional outcome 6 weeks, 6 and 12 months after fixation12 months postoperativeFunctional outcome 6 weeks, 6 and 12 months after fixation: the functional outcome will be recorded by the Quick Dash Score and the Constant at each follow up visit and compared between the two groups. Additionally, pain at either surgical site will be recorded via the visual analogue scale.
Safety12 months postoperativesafety: all adverse reactions will be recorded and analysed to assess the safety of the approach in a typical patient population.
bone mineral density12 months postoperativebone mineral density: in case of implant removal (see below) a 100 mm3 bone biopsy will be taken from the grafted area and analysed with MicroCT (micro computed tomography) for bone mineral density.
Histology12 months postoperativehistological assessment of qualitative and quantitative bone formation: bone biopsies will - after MicroCT assessment - be decalcified and histologically analysed using standard techniques and image quantification
Dose-response12 months postoperativeestablishment of a dose response relationship between number of implanted cells an bone quantity in microCT and histologically via image quantification: retrospectively the quantitative measures of bone formation will be correlated to the number of implanted cells and their clonogenicity

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026